Egalet Corp. (EGLT) Trading 4.8% Higher
Shares of Egalet Corp. (NASDAQ:EGLT) traded up 4.8% on Monday . The stock traded as high as $8.65 and last traded at $8.49, with a volume of 100,250 shares trading hands. The stock had previously closed at $8.10.
Several analysts have recently weighed in on the stock. Cantor Fitzgerald set a $21.00 target price on shares of Egalet Corp. and gave the company a “buy” rating in a research report on Saturday, August 6th. Zacks Investment Research lowered shares of Egalet Corp. from a “hold” rating to a “sell” rating in a research report on Thursday, May 12th.
The stock’s market cap is $201.99 million. The company’s 50-day moving average price is $6.44 and its 200-day moving average price is $6.59.
Egalet Corp. (NASDAQ:EGLT) last posted its quarterly earnings results on Thursday, August 4th. The specialty pharmaceutical company reported ($0.97) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.82) by $0.15. The business had revenue of $3.45 million for the quarter, compared to analysts’ expectations of $3.83 million. The company’s quarterly revenue was up 259.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.03) earnings per share. Equities research analysts predict that Egalet Corp. will post ($3.47) EPS for the current year.
In other Egalet Corp. news, CEO Robert S. Radie sold 5,000 shares of the company’s stock in a transaction on Friday, July 1st. The shares were sold at an average price of $5.07, for a total transaction of $25,350.00. Following the sale, the chief executive officer now directly owns 259,900 shares of the company’s stock, valued at $1,317,693. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Stan Musial sold 13,480 shares of the company’s stock in a transaction on Tuesday, July 5th. The stock was sold at an average price of $5.06, for a total transaction of $68,208.80. Following the sale, the chief financial officer now directly owns 84,940 shares in the company, valued at $429,796.40. The disclosure for this sale can be found here.
Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.